Brought to you by 
CStone closes $260mm Series B round; largest in Chinese biopharm history
01 Jun 2018
Executive Summary
Immuno-oncology firm CStone Pharmaceuticals Co. Ltd. raised $260mm through its Series B round, the largest funding of its kind in Chinese biopharma history. GIC Private Ltd. led and was joined by new investors Sequoia China, Yunfeng Capital, 6 Dimensions Capital, CITIC PE, Taikang Insurance Group, Arch Venture Partners, Hillhouse Capital, King Star Capital, 3W Partners, AVICT, and Terra Mafnum Capital Partners, as well as returning backers Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures. Funds will support continued development of lead candidate CS1001, an anti-PD-L1 mAb in Phase I/II for advanced cancers.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CStone closes $260mm Series B round; largest in Chinese biopharm history
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice